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Abstract
Sickle cell anemia (SCA) is associated with a hypercoagulable state. Increased platelet activation is reported in SCA and SCA
platelets may present augmented adhesion to the vascular endothelium, potentially contributing to the vaso-occlusive
process. We sought to observe the effects of platelets (PLTs) from healthy control (CON) individuals and SCA individuals on
endothelial activation, in vitro. Human umbilical vein endothelial cells (HUVEC) were cultured, in the presence, or not, of
washed PLTs from CON or steady-state SCA individuals. Supernatants were reserved for cytokine quantification, and
endothelial adhesion molecules (EAM) were analyzed by flow cytometry; gene expressions of ICAM1 and genes of the NF-kB
pathway were analyzed by qPCR. SCA PLTs were found to be more inflammatory, displaying increased adhesive properties,
an increased production of IL-1b and a tendency towards elevated expressions of P-selectin and activated aIIbb3. Following
culture in the presence of SCA PLTs, HUVEC presented significant augmentations in the expressions of the EAM, ICAM-1 and
E-selectin, as well as increased IL-8 production and increased ICAM1 and NFKB1 (encodes p50 subunit of NF-kB) gene
expressions. Interestingly, transwell inserts abolished the effects of SCA PLTs on EAM expression. Furthermore, an inhibitor
of the NF-kB pathway, BAY 11-7082, also prevented the induction of EAM expression on the HUVEC surface by SCA PLTs. In
conclusion, we find further evidence to indicate that platelets circulate in an activated state in sickle cell disease and are
capable of stimulating endothelial cell activation. This effect appears to be mediated by direct contact, or even adhesion,
between the platelets and endothelial cells and via NFkB-dependent signaling. As such, activated platelets in SCD may
contribute to endothelial activation and, therefore, to the vaso-occlusive process. Results provide further evidence to
support the use of anti-platelet approaches in association with other therapies for SCD.
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Introduction
Sickle cell anemia is a genetic disease caused by the production
of abnormal hemoglobin S (HbS), which polymerizes under
hypoxic conditions, resulting in the formation of sickled red blood
cells that are less flexible and are liable to lysis. These alterations
cause vaso-occlusive processes and hemolytic events that cause
irreversible damage to organs and manifestations, such as painful
vaso-occlusive crises, acute chest syndrome, stroke, osteonecrosis,
leg ulcers and cardiovascular disease [1]. The vaso-occlusive
process is the consequence of a complex pathophysiology that
involves chronic vascular inflammation, hypoxia-reperfusion
processes, oxidative stress and reduced nitric oxide bioavailability
with ensuing endothelial activation and the adhesion of red and
white cells to the vascular wall, leading to compromised blood flow
of the small and microcirculatory blood vessels [2].
Thrombotic complications, including ischemic stroke, can occur
in the sickle cell diseases (SCD) [3] and platelet activation and a
hypercoagulable state are now thought to contribute to SCD
pathophysiology [4]. Activation of the coagulation system and
augmented thrombin generation in SCD [5] is indicated by
reports of increased plasma levels of prothrombin fragment 1.2
(F1.2), thrombin anti-thrombin (TAT) [6,7] and D-dimer levels
[8], as well as augmented tissue factor (TF) expression in patients
[9–11]. Platelets of SCA patients (SCA platelets) are also known to
circulate in an activated state [12–14], presenting altered
aggregation [15,16] and increased adhesive properties under
static conditions [14]. SCA platelets are reported to present an
increased expression of adhesion molecules and markers of platelet
activation, such as CD40 ligand (CD40L), on their surface
[14,17,18] and produce higher levels of potent inflammatory
cytokines, such as TNFSF14 (Tumor necrosis factor ligand
superfamily member 14; LIGHT; CD258) [19]. Furthermore,
increased circulating levels of platelet microparticles and platelet-
derived proteins, such as thrombospondin-1 (TSP-1) and platelet
factor 4 (PF4), are a further indication of platelet activation in SCA
[13,20–22].
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The exact mechanism by which platelets may be activated in
SCD is not clear, but the release of adenosine diphosphate (ADP)
from lysed red blood cells may contribute to platelet activation
[23], and the exposure of phosphatidyl serine (PS) on the surface of
sickle red blood cells is also suggested to activate platelets, via
induction of thrombin generation [24,25] and a consequent
reduction in intraplatelet cAMP (cyclic adenosine monophosphate)
[14]. Low nitric oxide (NO) bioavailability may also activate
platelets in SCD [2]. Additionally, SCD platelets can form
circulating heterocellular aggregates with monocytes and neutro-
phils, where the adhesion of platelets to these leukocytes is
suggested to participate in their activation and subsequent
adhesion to the endothelium [26,27]. Activated aIIbb3 expression
has also been previously correlated to the severity of pulmonary
hypertension in SCD and to laboratory markers of hemolysis, such
as reticulocyte counts [28].
While a role for the platelet in SCD pathophysiology seems
apparent, whether the platelets have a direct role in the vaso-
oclusive process is not clear. We hypothesize that the close
proximity or adhesion of activated platelets to the vascular
endothelium may contribute to the activation of endothelium in
SCD, an event that is central to the vaso-occlusive process. We
sought to observe the effects of platelets from healthy individuals
and SCA individuals on the expression and production of
adhesion molecules and inflammatory proteins by endothelial
cells in vitro, and to investigate the signaling pathway that may
mediate this effect.
Patients and Methods
Materials
Human fibrinogen and BAY 11-7082 ((E)3-[(4-Methylphenyl)-
sulfonyl]-2- propenenitrile) were purchased from Calbiochem (La
Jolla, CA, USA); Ham’s F12K medium was from Gibco-
Invitrogen (Carlsbad, CA, USA). Collagen type I, fetal bovine
serum and trypsin/ethylenediaminetetraacetic acid (EDTA) solu-
tion were obtained from Sigma-Aldrich (Saint Louis, MO, USA).
Recombinant TNF-a and ELISAs for interleukin-8 (IL-8),
interleukin-1b (IL-1b) and Platelet Factor 4 (PF4) determination
were from R&D Systems (Minneapolis, MN, USA). ACD
VacutainersH were used for blood collection (BD Brasil, Sao
Paulo, Brazil). All other products were from Sigma-Aldrich unless
otherwise stated.
Patients
A total of 90 steady-state SCA patients (between 18-53 years
old) were recruited from the Hematology and Hemotherapy
Center, University of Campinas, Brazil and from the Boldrini
Children’s Center for Hematologic Investigations, Campinas,
Brazil. All patients were diagnosed as homozygous for HbS (using
hemoglobin electrophoresis methods and high performance liquid
chromatography). All patients attended regular clinics and had not
experienced painful crisis nor received blood transfusions in the
preceding 3 months and had not taken aspirin during the previous
10 days. Patients on hydroxyurea (HU) therapy had been taking
15–30 mg/kg per day for at least 3 months. A total of 55 healthy
volunteers (between 19–61 years old) were recruited at the same
centers. None of the controls had taken any medication within the
last 10 days and controls were age- and gender-matched where
possible. See Table 1 for clinical details of participating patients
and healthy controls.
Ethics Statement
Informed written consent was obtained from all patients and
controls and the study was approved by the Ethics Committees of
the University of Campinas, Brazil and of the Boldrini Children’s
Center, Campinas, Brazil (Reg. no. 1170/2009). All clinical
investigations were conducted in accordance with the Declaration
of Helsinki.
Preparation of washed platelets
Platelet rich plasma (PRP) was obtained by centrifugation of
whole blood (collected in 22.0 g/L trisodium citrate, 8.0 g/L citric
acid, 24.5 g/L dextrose) at 200 g, 21uC for 20 min. PRP was
washed once in wash buffer (140 mmol/l NaCl, 5.0 mmol/l KCl,
12 mmol/l sodium citrate, 10 mmol/l glucose and 12.5 mmol/l
sacarose, pH 6) and platelets (PLTs) were isolated from the PRP
by centrifugation at 800 g at 21uC for 12 min. The platelet pellet
was then resuspended in F-12K medium (GIBCO life Technol-
ogies, Grand Island, NY, USA). Platelet counts were performed
using a Beckman Coulter cell counter (Fullerton, CA, USA).
Suspensions were utilized immediately in assays; the anticoagulant
utilized did not affect assay results. Control and SCD platelets
were treated in the same manner and always run in parallel in
platelet assays; thus, differences in properties of platelets reflect
differences inherent to these platelets, and are not due to the
separation/washing procedure.
Microfluidic platelet adhesion assay
The VenafluxTM microfluidic platform (Cellix Ltd, Dublin,
Ireland) was used to measure platelet adhesion to fibrinogen (FB,
50 mg/mL) and collagen (Col, 100 mg/mL) under physiologically
relevant conditions. Unwashed PRP was obtained from control
individuals and/or SCA patients and resuspended in phosphate
buffered saline (PBS, pH = 7.4; 16107 PLTs/mL) to monitor
adhesion to biochips (400 mm-wide Vena 8 microchannels, Cellix,
Dublin, Ireland) that were pre-coated (2 h, room temperature)
with FB or Col and subsequently blocked with 1% BSA/PBS.
Platelets were perfused over micro channels at a shear stress of 0.3
dyne/cm2 for 3 min at 37uC; adhesion was detected using
brightfield inverted microscopy and images were acquired with a
DeltaPix camera (Carl Zeiss Inc, Jena, Germany; 406 magnifi-
cation; DeltaPix Camera, Maalov, Denmark). The adhesion of
platelets to duplicate microchannels was recorded at three
positions in the channel and analyzed using the DucoCell analysis
program (Cellix Ltd), recording the mean number of platelets
adhered to an area of 3306250 mm (0.08 mm2).
Culture of endothelial cells
Human Umbilical Vein Endothelial Cells (HUVEC) were
purchased from the American Type Culture Collection (ATCC)
(Manassas, VA, USA) and cultured in 75 cm2 flasks, and 6-well
tissue culture plates with Ham’s 12K medium supplemented with
endothelial cell growth supplement factor (ECGS; 0.5 mg/mL),
heparin (0.1 mg/mL) and fetal bovine serum (10%). Cells were
used at the fourth to sixth passage and cultures were maintained at
37uC in a humidified atmosphere with 5% CO2; the medium was
replaced every 2 days until confluence (3–5 days).
In vitro co-culture assay
HUVEC were co-cultured (16106 cells/well, 4 h, 37uC, 5%
CO2) in the presence or absence of PLTs (1610
8 PLTs/well). In
some cultures, transwell inserts (0.4 mm pores) were used to
separate PLTs from HUVEC. For some experiments, HUVEC
were also incubated with TNF-a (10 ng/mL in medium) (3 h,
Endothelial Activation by SCA Platelets
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37uC, 5% CO2) as a positive endothelial activation control. For
other experiments, HUVEC were pretreated with BAY 11-7082
(20 mM) or vehicle (0.02% dimethylsulfoxide) for 30 min (37uC,
5% CO2) before performance of the co-culture assays. After
incubation, PLTs were removed and the supernatants were stored
(280uC) for cytokine quantification by ELISA. HUVECs were
washed once with PBS and detached with trypsin/EDTA solution
(4 min, 37uC) for flow cytometry or quantitative PCR (qPCR).
Flow Cytometry
After incubations, the PLTs were removed from cultures;
HUVECs were washed once with PBS and detached with trypsin/
EDTA solution trypsin (0.25%). Antibodies used for flow
cytometry to recognize endothelial adhesion molecules were all
purchased from BD Pharmingen (San Diego, CA, USA); anti-
CD62P-fluorescein isothiocyanate (FITC; P-selectin; clone AK-4),
PAC-1-FITC (recognizes aIIbb3 in its activated conformation),
anti-CD54-phycoerythin (PE; ICAM-1, clone LB-2), anti-CD106-
FITC (VCAM-1, clone 5110C9) and anti-CD62E-Allophycocya-
nin (APC; E-selectin, clone 68-5H11). Flow cytometric analysis (10
000 events) was performed using a FACSCalibur flow cytometer
and BD FACS DIVA 7.0 software (BD, San Jose, CA, USA).
Possible alterations in HUVEC phenotype and activation state
following trypsin treatment should not be overlooked; however
control and experimental HUVEC were treated with trypsin in a
similar manner and differences between groups were therefore not
the consequence of trypsin application.
Quantification of IL-8, IL-1b and PF4 in culture
supernatants
Levels of IL-8, IL-1b and PF4 were determined in the
supernatants of platelets cultured for 4 h (16108 PLTs/well;
37uC, 5% CO2) and of co-cultures (4 h, 37uC, 5% CO2) of
HUVEC (16106 cels/well) with platelets (16108 PLTs/well) using
commercial high-sensitivity ELISAs, according to the manufac-
turer’s instructions (R&D Systems).
Quantification of endothelial gene expressions of ICAM1,
NFKB1, RELA, CHUK and IKKBETA by qPCR
Extraction of mRNA from HUVEC (1–56105 cells) was
performed with the RNeaseyH Micro Kit (QIAGEN Biotecnologia
Brasil Ltda, Sa˜o Paulo, Brazil) and cDNA synthesized using a
reverse-transcription kit (Thermo Scientific, Waltham, MA, USA).
Synthetic oligonucleotide primers were designed to amplify cDNA
for conserved regions of the ICAM1 (encodes Intercellular
Adhesion Molecule 1 protein), NFKB1 (encodes the p50 subunit
of nuclear factor-kB [NF-kB]), RELA (encodes the p65 subunit of
NF-kB), CHUK (encodes the IkBa inhibitor protein for NF-kB)
and IKKBETA (encodes the I b kinase protein for NF-kB) genes
by Primer-Express (Applied Biosystems, Foster City, CA, USA).
For primer sequences, see Table 2. Primers were synthesized by
Invitrogen (Sa˜o Paulo, Brazil) and ACTB and GAPDH were used as
internal control genes. All samples were assayed in a 12 mL volume
containing 5 ng cDNA, 6 mL SYBR Green Master Mix PCR
(Applied Biosystems, Foster City, California, USA) and gene
primers (7500 Fast Real-Time PCR System – Applied Biosystems).
To confirm accuracy and reproducibility of real-time PCR, the
intra-assay precision was calculated according to the equation: E(-
1/slope). The dissociation protocol was performed at the end of each
run to check for non-specific amplification. Two replicas were run
on the plate for each sample. Results are expressed as arbitrary
units (A.U.) of gene expression, when compared with the control
genes.
Statistical analysis
Data are depicted as median values and groups were compared
by unpaired nonparametric analysis of variance (ANOVA)
followed by Kruskal-Wallis Comparisons test, or the unpaired
nonparametric Mann-Whitney test for comparisons between two
groups. P,0.05 was considered to be significant.
Results
Platelets from SCA patients demonstrate altered
expressions and productions of adhesion molecules and
inflammatory proteins
Platelets of SCA individuals are known to circulate in a
partially-activated state. Accordingly, platelets from individuals of
our SCA population were found to express a number of
inflammatory molecules (Figure 1). Platelets from healthy control
individuals and SCA individuals (CON PLTs and SCA PLTs,
respectively) were incubated in culture medium for 4 h at 37uC
and the productions of the cytokines, IL-1b, platelet factor 4 (PF4)
Table 1. Demographic, clinical and hematological details of all controls and patients participating in the study.
CONTROLS SCA p
Male/female 18/37 46/44
Age (years) 34.1 (31; 24, 58) 34.3 (32; 18; 53)
Hydroxyurea therapy (n) - 56
Red blood cell count (106/mL) 4.70 (4.64; 3.79; 5.60) 2.61 (2.61; 1.63; 4.78) p,0.001
Hematocrit (%) 39.9 (39.5; 32.1; 48.4) 24.8 (22.6; 17.; 37.4) p,0.001
Hemoglobin (g/dL) 13.5 (13.3; 10.9; 15.6) 8.5 (8.0; 6.0; 12.9) p,0.001
Mean corpuscular volume (fL) 84.6 (84.3; 74.9; 95.7) 96.1 (93.8; 69.2; 126.6) p,0.001
Mean corpuscular hemoglobin (pg) 28.8 (29.0; 25.2; 30.8) 33.4 (33.1; 20.9; 47.0) p,0.01
WBC (103/mL) 6.1 (5.90; 3.6; 8.9) 9.6 (9.5; 4.0; 22.3) p,0.001
HbF (%) 0.4 (0.3; 0.1; 1.7) 10.6 (8.7; 0.8; 27.2) p,0.001
PLTs (103/mL) 293 (276; 208; 428) 375 (355; 156; 711) p,0.01
SCA, steady-state SCA patients; hydroxyurea therapy (20–30 mg/kg/day for at least 3 months); HbF, fetal hemoglobin. Data present (except M/F value) are mean
(median, min, max).
doi:10.1371/journal.pone.0089012.t001
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and IL-8 (Figure 1A–C) were determined by ELISA. While no
significant alterations in the release of IL-8 or PF4 by SCA PLTs
were observed (Fig. 1B, Fig. 1C), compared to control PLTs, IL-1b
release by SCA PLTs was significantly increased for SCA PLTs.
Flow cytometric analysis found the expression of the adhesion
molecule, P-selectin (Figure 1D), to be increased on SCA PLTs
(P = 0.06), but not quite significantly, while the aIIbb3 integrin was
found in a more activated state on SCA PLTs (Figure 1E), as
demonstrated by increased PAC-1 antibody binding. When PLT
data were stratified into those PLTs that were from SCA patients
on HU therapy and those that were not, no significant differences
were found between any of these parameters for these two patient
groups (P.0.05), with the exception of the expression of activated
aIIbb3 integrin, which was found to be higher on PLTs from
patients not on HU (30.266.6%, n = 16), compared to those on
HU (11.664.1, n = 14; P = 0.05).
SCA platelets demonstrate alterations in adhesive
properties in a microfluidic assay
We have previously shown that platelets demonstrate an
augmented capacity to adhere to fibrinogen ligand under static
assay conditions [14,29]. In accordance with these previous
findings, using a microfluidic platform, SCA PLTs were found to
adhere significantly more, under flow conditions, to microchannels
coated with fibrinogen (See Figure 2A), but not to collagen
(Figure 2B). No significant differences were found between the
ability of platelets from SCA individuals and SCA patients on HU
to adhere to fibrinogen or collagen (P.0.05), although the low
experimental number employed for the SCA group may have
limited the detection of any possible differences in adhesive
properties.
SCA platelets induce the expression of the adhesion
molecules, ICAM-1 and E-selectin, on the surface of
HUVEC
Flow cytometry was utilized to compare the surface expressions
of CD54 (ICAM-1), CD62E (E-selectin) and CD106 (VCAM-1)
on HUVEC following their incubation, or not, with platelets.
Confluent HUVEC were co-cultured in direct contact with
platelets (16108 PLTs/well) from control individuals (CON
PLTs), SCA patients (SCA PLTs) or culture medium for 4 h
(37uC, 5% CO2). HUVEC cultured with CON PLTs demon-
strated a non-significant increase in surface ICAM-1 and E-
selectin (FIGURE 3A and 3B); in contrast, SCA PLTs induced a
significant increase in both ICAM-1 and E-selectin on HUVEC
(FIGURE 3A and 3B), while VCAM-1 expression was not induced
by either type of PLT (FIGURE 3C). A TNF-a-inflammatory
stimulus (10 ng/mL) was used as a positive control to observe the
effect of a strong inflammatory stimulus on adhesion molecule
expression on HUVEC (FIGURE 3).
PLTs from SCA patients on HU (SCAHU) therapy and from
those patients not on HU demonstrated similar effects on HUVEC
adhesion molecule expression, with no significant differences
between the two subgroups. Mean CD54 (ICAM-1) expression on
HUVEC following incubation (4 h, 376C) with SCA and
SCAHU platelets was 43.463.2% and 38.864.00%, respectively
(n = 15 and 19); Mean CD62E (E-selectin) expression on HUVEC
following incubation (4 h, 37uC) with SCA and SCAHU platelets;
2.9160.93% and 7.7863.44%, respectively (n = 15 and 16); Mean
CD106 (VCAM-1) expression on HUVEC following incubation
(4 h, 37uC) with SCA and SCAHU platelets; 1.4460.24% and
1.1660.21%, respectively (n = 17 and 8) (P.0.05 for all compar-
isons). As such, all results for both SCA and SCAHU individuals
are depicted together in the figures for the HUVEC experiments
and data were analyzed together in the same group (SCA).
Transwell inserts abolish the effects of the induction of
endothelial adhesion molecule expression by platelets
Repetition of these assays, but with the placement of transwell
polystyrene membrane inserts (0.4 mm pores) in culture plates, to
physically separate the PLTs from HUVEC, completely abolished
the effects of CON and SCA PLTs on ICAM-1 (CD54) expression
(FIGURE 4A) and the effect of SCA platelets on E-selectin
(CD62E) expression (Figure 4B). Data indicate that close contact,
or possibly adhesion, of the platelets with the HUVEC is required
for activation of endothelial adhesion molecule expression.
Table 2. Primer sequences for performance of real-time quantitative PCR.
Genes Primers Optimal concentration (nM)
ICAM1 - F 59-GGAAATACTGAAACTTGCTGCCTAT-39 150
ICAM1 - R 59-ACACATGTCTATGGAGGGCCAC-39
NFKB1 - F 59-GCTTTTGGTGTCCTTGGGT-39 70
NFKB1 - R 59-AGGTCCACTGCGAGGTGA-39
RELA - F 59-CACCTCGACGCATTGCTGT-39 70
RELA - R 59-GACGTAAAGGGATAGGGCTGG-39
CHUK - F 59-ACCAGCATCGGGAACTTGATC-39 70
CHUK - R 59-TGGCACCATCGTTCTCTGTTT-39
IKKBETA- F 59-ATCTCCGGAAGTACCTGAACCA-39 70
IKKBETA- R 59-AGCGCAGAGGCAATGTCACT-39
ACTB - F 59-AAAGAGATGGCCACGGCTGCT-39 150
ACTB - R 59-TCGCTCCAACCGACTGCTGT-39
GAPDH - F 59-GCACCGTCAAGGCTGAGAAC-39 150
GAPDH - R 59-CCACTTGATTTTGGAGGGATCT-39
ACTB, encodes b-actin protein; CHUK, encodes IkBa protein; GAPDH, encodes glyceradehyde 3-phosphate dehydrogenase; ICAM1, encodes ICAM-1 protein; IKKBETA,
encodes IKKb protein; NFKB1, encodes p50 protein; RELA, encodes p65 protein.
doi:10.1371/journal.pone.0089012.t002
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SCA PLTs increase the production of interleukin-8 (IL-8)
by endothelial cells
IL-8 is an important inflammatory cytokine and can be
produced and released by endothelial cells under basal conditions.
Production of IL-8 was significantly augmented in HUVEC
cultures that were co-cultured in the presence of SCA PLTs,
compared to basal levels of production by non-stimulated
HUVEC (FIGURE 5). CON PLTs had no significant effect on
IL-8 levels in HUVEC cultures, while TNF-a significantly
increased IL-8 secretion by HUVEC. Platelets also produce and
release IL-8, but at low levels when compared to IL-8 production
by HUVEC (See Figure 1B); thus it seems likely that the IL-8
observed in these cultures may be produced primarily by
stimulated HUVEC.
Figure 1. Platelets as inflammatory cells in SCA. Release of (A) IL-1b, (B) IL-8, (C) platelet factor 4 (PF4) from platelets of healthy control
individuals (CON) and SCA patients in steady state (SCA). Cytokine release was determined by ELISA in platelet suspensions (16108 PLT/ml) after
incubation for 4 h (37uC, 5% CO2). Expressions of (D) P-selectin and (E) activated aIIbb3 integrin on the surface of platelets from healthy control
individuals (CON) and SCA patients in steady state (SCA). Medians and interquartile ranges are depicted. Adhesion molecule expression was
determined by flow cytometry. Some of the data included in the data sets depicted in graphs 1D and 1E have been previously published in table
form [14]. Closed black square symbols represent SCA patients not on HU therapy; open grey square symbols represent patients on HU (15–30 mg/
kg/day) therapy.
doi:10.1371/journal.pone.0089012.g001
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Co-culture of HUVEC with SCA platelets induces gene
expression of endothelial ICAM1 and genes of the NF-kB
pathway
The effect of co-culture of PLTs with HUVEC on endothelial
gene expression was determined by quantitative real-time PCR
(qPCR). Confluent HUVEC were co-cultured in direct contact
with platelets from control individuals (CON PLTs), SCA patients
(SCA PLTs) or culture medium for 4 h (37uC, 5% CO2); PLTs
were removed by gentle washing and HUVEC gene expression
determined. Relative gene expression of ICAM1 increased by 6.9-
fold in endothelial cells in the presence of SCA PLTs, compared to
basal expression, but was not altered in the presence of CON
PLTs (FIGURE 6A). In contrast, TNF-a increased the ICAM1
gene expression in HUVEC by 93-fold, when compared to basal
expression (FIGURE 6A). The nuclear transcription factor, NF-
kB, is a cytoplasmic protein that when activated translocates to the
nucleus, under the control of proteins of the NF-kB pathway,
inducing the gene expression of a number of genes, including
inflammatory molecules, growth factors, and cell adhesion
molecules [30,31]. Following the incubation of HUVEC with
SCA PLTs, but not CON PLTs, the expression of the NFKB1 gene
(encodes p50 subunit of NF-kB) was significantly increased in
HUVEC (Figure 6B). In contrast, the expressions of the CHUK
gene (encodes IkBa inhibitor protein), the IKKBETA gene (I B
kinase) and RELA (encodes the p65 subunit, forming a heterodi-
mer with p50) by HUVEC were not affected by co-incubation of
Figure 2. Adhesive properties of platelets. A microfluidic assay
was used to determine the adhesion of platelets from healthy control
individuals (CON) and SCA patients in steady state (SCA) to (A) 50 mg/ml
fibrinogen and (B) 100 mg/ml collagen. Platelets (16107 PLTs/mL) were
perfused over microchannels (400 mm width) coated with immobilized
ligands at a shear stress of 0.3 dyne/cm2 for 3 min at 37uC; adhesion
was detected using brightfield inverted microscopy. The adhesion of
platelets to duplicate microchannels was recorded at three positions in
each channel and analyzed using the DucoCell analysis program,
recording the mean number of platelets adhered to an area of
0.08 mm2. Medians and interquartile ranges are depicted. Closed black
square symbols represent SCA patients not on HU therapy; open grey
square symbols represent patients on HU (15–30 mg/kg/day) therapy.
doi:10.1371/journal.pone.0089012.g002
Figure 3. Effects of platelets on endothelial adhesion molecule
expression. Surface expressions of (A) ICAM-1 (CD54), (B) E-selectin
(CD62E) and (C) VCAM-1 (CD106) adhesion molecules on HUVEC
following co-culture in direct contact with healthy control (CON; N$15)
PLTs, steady-state sickle cell anemia (SCA; N$25) PLTs or TNF-a (N$11).
HUVEC (16106 cells/well) were incubated with CON or SCA PLTs
(16108 PLTs/well) for 4 h (37uC, 5% CO2), or with TNF-a, (10 ng/ml; 3 h,
37uC, 5% CO2). Expression of ICAM-1, E-selectin or VCAM-1 was
analyzed on HUVEC (10 000 cells) by flow cytometry using anti-CD54-
PE, CD62E-APC and CD106-FITC. **, p,0.01; ***, p,0.001, compared to
basal (N$16).
doi:10.1371/journal.pone.0089012.g003
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cells with PLTs (Figure 6C, D and E). Incubation of HUVEC with
TNF-a significantly increased the expressions of NFKB1 and
RELA.
Inhibition of the NF-kB pathway abolishes the induction
of ICAM-1 and E-selectin on HUVEC by SCA PLTs
To determine whether the NF-kB signaling pathway mediates
the SCA PLT-induced expression of adhesion molecules on the
surface of HUVEC, co-cultures of HUVEC and PLTs were co-
incubated with BAY 11-7082. BAY 11-7082 selectively and
irreversibly inhibits phosphorylation of IkBa, resulting in a
decreased activation of NF-kB [32]. BAY 11-7082 (20 mM)
significantly decreased the expressions of both ICAM-1 (CD54)
and E-selectin (CD62E) on the surface of HUVEC, when cells
were co-cultured in the presence of SCA PLTs (FIGURE 7A). The
less significant increase in ICAM-1 expression on HUVEC
following incubation of cells with CON PLTs was also abolished
by BAY 11-7082 (Figure 7A). Activation of HUVEC by TNF-a, as
demonstrated by induction of ICAM-1 expression was also
abolished by BAY 11-7082 (data not shown).
Discussion
Previous reports consistently indicate that platelets circulate in
an activated, or partially activated, state in SCD [13]. According-
ly, despite a relatively low experimental number with a limited
power to detect significant differences, platelets isolated from our
current cohort of patients with SCA presented a trend towards an
increased expression of markers of platelet activation, including P-
selectin, and an increased presentation of the aIIbb3 integrin in its
activated conformation. Additionally, the production of the
inflammatory cytokine, IL-1b, was augmented in SCA platelets.
Previous reports on the inflammatory nature of SCA platelets
indicate that SCA platelets also release increased levels of other
potent cytokines such as TNFSF14 (LIGHT) and CD40L [19], as
well as microparticles. In a previous study, we demonstrated an
augmented aiibb3-dependent adhesion of SCA platelets, under
static conditions [14]. We, herein, present data from a physiolog-
ically relevant microfluidic assay to support evidence to indicate
that platelets from SCA individuals demonstrate increased
adhesive properties. SCA platelets demonstrated increased adhe-
sion to fibrinogen, compared to platelets from control individuals,
strengthening our hypothesis that the adhesion of inflammatory
SCA platelets to components of the blood vessel wall may be
important in sickle cell disease.
Platelets from both healthy control individuals and SCA
individuals were found to induce the expression of major
endothelial adhesion molecules, ICAM-1 and E selectin, on the
surface of HUVEC; notably the ability of SCA platelets to induce
this expression was more significant and, depending on the SCA
individual, levels of expression of these molecules reached levels
induced by TNF-a induction. ICAM1 gene expression by HUVEC
was also induced by SCA platelets. ICAM-1 is an important ligand
for leukocyte adhesion to the endothelium, while E-selectin-
mediated endothelial interactions are also thought to play a role in
activating leukocyte integrins, consequently increasing leukocyte
adhesive properties and heterotypic interactions with other cell
types [33]. Given the primary role that the adhesion of leukocytes
to the vessel wall is thought to play in the vaso-occlusive process,
the stimulation of endothelial-leukocyte adhesion molecule
expression by activated platelets, may be important in SCD.
Further evidence of the activation of the endothelium was
provided by the observation that some cultures of HUVEC and
SCA platelets, depending on the individual, produced higher levels
of IL-8 cytokine than either HUVEC or SCA platelets alone.
Figure 4. Transwell inserts reverse the effects of SCA platelets
on endothelial adhesion molecules expression. Surface expres-
sions of (A) ICAM-1 (CD54) and (B) E-selectin (CD62E) adhesion
molecules on HUVEC (16106 cells/well) following culture in the
presence of healthy control (CON; N$6; 16108 PLTs/well) PLTs or
steady-state sickle cell anemia (SCA; N $12; 16108 PLTs/well) PLTs and
in the presence and absence of transwell inserts (0.4 mm pores).
Expressions of ICAM-1 and E-selectin were evaluated by flow cytometry
using anti-CD54-PE and CD62E-APC. *, p,0.01; ***, p,0.001, compared
to basal (N = 9).
doi:10.1371/journal.pone.0089012.g004
Figure 5. Release of IL-8 from co-cultures of HUVEC and PLTs.
Levels of IL-8 (ng/ml) were quantified in supernatants of co-cultures of
HUVEC (16106 cells/well) (4 h in suspension, 37uC, 5% CO2) in direct
contact with CON (n= 27) or SCA PLTs (16108 PLTs/well; n = 44), (4 h,
37uC, 5% CO2); or following pre-incubation of HUVEC with TNF-a
(10 ng/ml; N= 24; 3 h, 37uC, 5% CO2). ***, P,0.001, compared to basal
(N = 24); +++, P,0.001, compared to all groups.
doi:10.1371/journal.pone.0089012.g005
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Importantly, the significant effect of SCA platelets on the
expression of both ICAM-1 and E-selectin on the surface of
HUVEC was almost abolished by the insertion of 0.4 mm-pore
transwell inserts in culture wells to separate the platelets from the
endothelial cells. Data indicate that either close contact or, even,
the adhesion of SCA platelets to HUVEC is required for
endothelial activation by SCA platelets, rather than being an
effect that is dependent just upon the release of inflammatory
molecules by platelets. Platelets from SCA individuals are known
to produce increased quantities of microparticles, which could play
a role in endothelial activation. In addition to their pro-
coagulatory properties, microparticles released from activated
platelets can be internalized by endothelial cells, where they can
release miR-223 and Ago2NmiR-233, both able to regulate
endothelial gene expression [34]. However, while platelet micro-
particles have been related to measure up to 1 mm in size, flow
cytometry analyses indicate that microparticles released from both
resting and activated platelets measure predominantly between
0.1–0.4 mm. As such, it seems likely that the 0.4 mm-transwell
inserts employed herein would not prevent the majority of platelet
microparticles from reaching the endothelial cells, further
supporting the hypothesis that direct contact between the platelets
and the endothelium induced the alterations observed, although
the participation of platelet MP release cannot be ruled out.
Interestingly, SCA platelets induced the gene expression of
NFKB1, encoding the p50 subunit of the NFkB transcription
factor. Furthermore, an inhibitor of NFkB signaling, BAY 11-
7082, reversed the effects of both CON and SCA platelets on the
induction of ICAM-1 expression by HUVEC and inhibited the E-
selection expression induced by SCA platelets. These data indicate
that activation of endothelial cells by SCA platelets appears to
occur via an NFkB-dependent signaling pathway. Similarly,
activated monocytes from SCD individuals have been previously
found to activate endothelial cell cultures in a cytokine- and
NFkB-dependent manner; however, cell-to-cell contact was not
required for the effect of activated monocytes on endothelial cells
[35]. Such reports reinforce the multicellular nature of inflamma-
tion, endothelial activation and ensuing vaso-occlusion in SCD.
In the present study, data were acquired using platelets isolated
both from steady-state SCA patients that were not in use of
hydroxyurea (HU) and also from patients in use of HU. Statistical
analyses revealed that the use of HU did not significantly alter the
effect of SCA platelets on endothelial activation, although the
relatively low experimental number employed may limit the ability
to detect such differences. Moreover, in some cases, platelets from
some patients that were on HU therapy activated endothelium
more than platelets from some patients not on HU. While we
previously [14] found that HU therapy may be associated with a
Figure 6. Effect of SCA platelets on endothelial gene expression. Relative gene expression of (A) ICAM1, (B) NFKB1, (C) RELA, (D) CHUK and (E)
IKKBETA in HUVEC after co-culture with PLTs. HUVEC (16106 cells/well) were co-cultured in direct contact with CON (N=10) or SCA PLTs (N$24;
16108 PLTs/well) (4 h, 37uC, 5% CO2); or pre-incubated with HUVEC with TNF-a (10 ng/ml; N$11; 3 h, 37uC, 5% CO2). Relative gene expressions were
determined by qPCR and expressed relative to ACTB and GAPDH expressions. *, P,0.05; **,P,0.01, compared to basal (N$11). +++, P,0.001,
compared to all groups.
doi:10.1371/journal.pone.0089012.g006
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reduction in platelet activation, more recent studies increasingly
reveal some alterations in the current pathophysiological profile of
SCA patients. HU therapy, for example, has been associated with
an increase in platelet-derived plasma thrombospondin-1 in SCD
patients [21] and platelet-derived TNFSF14 (LIGHT) cytokine
and CD40L are not significantly altered in SCA patients on HU,
compared to those not on HU [19]. Due to the ethical issues of
discontinuing HU therapy in patients that fill the criteria for the
use of this drug, and the transversal nature of these studies cited, it
is difficult to determine whether HU therapy has no significant
effect upon some aspects of platelet activation or inflammatory
status, or whether, as previously suggested [21], HU therapy is
now so widely used for patients with more severe SCA that, at
some centers, nearly all those patients that are not in use of HU
represent the patients with the mildest phenotype. Longitudinal
studies would be required to establish whether HU therapy has an
effect on the inflammatory status of SCA platelets.
The potential benefits of antiplatelet medications have long
been discussed for SCD; earlier studies to investigate the effects of
aspirin, dipyridamole and heparin, however, were inconclusive
[36–39]. More recent ongoing trials of antiplatelet agents include
those that have employed prasugrel, a P2Y(12) adenosine
phosphate (ADP) receptor antagonist that inhibits platelet
activation and aggregation, and eptifibatide, an aiibb3-integrin
antagonist, that has also been used during acute pain episodes [40–
43].
In conclusion, we find further evidence to indicate that platelets
circulate in an activated state in sickle cell disease, demonstrating
augmented inflammatory and adhesive properties. SCA platelets
are capable of stimulating endothelial cell activation, as demon-
strated by the induction of the increased expression of endothelial
inflammatory and adhesive proteins. This effect appears to be
mediated by direct contact, or even adhesion, between the
platelets and endothelial cells and via an NFkB-dependent
signaling pathway. In addition to the increased adhesive properties
displayed by SCA platelets, it should not be forgotten that
numbers of circulating platelets are generally considerably higher
in SCA, as such both the quantity and activation state of platelets
Figure 7. Effect of inhibition of the NF-kB pathway on the induction of endothelial adhesion molecule expression by SCA PLTs. The
expressions of (A) ICAM-1 (CD54) and (B) E-selectin (CD62E) were determined by flow cytometry on HUVEC (16106 cells/well) following co-culture in
direct contact with CON PLTs (N$13) or SCA PLTs (16108 PLTs/well; N$14) in the presence or absence of BAY 11-7082 (20 mM; 4 h, 37uC, 5% CO2). *,
P,0.05; **, P,0.01, compared to basal (N$12).
doi:10.1371/journal.pone.0089012.g007
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may contribute to endothelial activation and, therefore, the vaso-
occlusive process in sickle cell disease and provide further evidence
to support the use of anti-platelet approaches in association with
other therapies for SCD.
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